240 results on '"Monkhorst K"'
Search Results
2. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics
3. Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments
4. Optimising primary molecular profiling in non-small cell lung cancer.
5. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer
6. P2.10-07 ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases
7. Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath
8. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project
9. 191P ROS1 fusions in resected stage I-III adenocarcinoma (ADC): A Lungscape ETOP study
10. Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
11. Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma
12. Upfront Resection of Locally-Advanced And/Or Cavitating Nsclc Followed by Chemoradiotherapy (and Adjuvant Systemic Treatment); Phase 1 Multicenter Study to Assess Treatment Feasibility and Safety (NVALT32/UPLAN-I Trial)
13. 40P Can we predict which TIL products will react against NSCLC tumours based on the immune infiltrates?
14. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients-correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (Oct, 10.1038/s41379-022-01170-z, 2022)
15. 1045P Comprehensive genomic profiling to guide immunotherapy in lung cancer
16. 1673P Exploring different strategies to incorporate germline analysis in tumor whole genome sequencing
17. 1075P Tobacco smoking related mutational signatures (MS) in classifying smoking and non-smoking associated metastatic non-small cell lung cancer (mNSCLC)
18. CELL-FREE DNA AS A NEW BIOMARKER FOR MONITORING LUNG CANCER: Mon, 23 h16.30 - Role of biomarkers in precision medicine
19. T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial
20. MA02.07 T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial
21. MA07.03 Paired Liquid and Tissues Biopsies to Guide Treatment for Patients That Progress on 2nd Line Osimertinib Treatment
22. Biologic meshes are not superior to synthetic meshes in ventral hernia repair: an experimental study with long-term follow-up evaluation
23. 1133P Whole genome sequencing can classify diagnostically challenging tumors
24. 1740P Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to second-line osimertinib treatment in patients with EGFR mutation positive (EGFRm) NSCLC
25. 1723P Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands
26. 1249P Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
27. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
28. 10P Impact of the number of metastatic lymph nodes on survival in pathological stage II-N1 non-small cell lung cancer
29. 136P Best practice recommendations for molecular analysis of acquired EGFR TKI resistance mechanisms
30. Identification of epithelialization in high transsphincteric fistulas
31. MA06.03 Phosphorylated Ribosomal Protein S6, Correlation With Characteristics and Clinical Outcome in Patients With MPM: Results from ETOP Mesoscape
32. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
33. 1189O Validation of whole genome sequencing in routine clinical practice
34. The force of HER2 – A druggable target in NSCLC?
35. Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma
36. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
37. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib
38. Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
39. IBS06.01 Realtime Data from Europe ETOP / ESTS Database
40. WGS implementation in standard cancer diagnostics for every cancer patient (WIDE)
41. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
42. Realtime Data from Europe ETOP / ESTS Database
43. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project
44. Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative
45. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: Results from the ETOP Lungscape Project
46. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
47. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort
48. P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
49. MA26.06 Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative
50. Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.